Table 3.
Percentage of samples in each group categorized according to the inflammatory score, macrophage score and necrosis at each time point.
| Material | Inflammatory Score * | Macrophage † | Necrosis # | ||||||
|---|---|---|---|---|---|---|---|---|---|
| 0 | 1 | 2 | 3 | 0 | 1 | 2 | 0 | 1 | |
| 7 days | |||||||||
| Control | 20.6 | 20.6 | 23.5 | 35.3 | 41.2 a | 47.1 a | 11.8 a | 61.8 | 38.2 |
| MTA | 8.8 | 8.8 | 35.3 | 47.1 | 17.6 b | 82.4 b | 0 b | 41.2 | 58.8 |
| iRoot SP | 5.9 | 11.8 | 41.2 | 41.2 | 17.6 a | 70.6 a | 11.8 a | 47.1 | 52.9 |
| BC Sealer HiFlow | 8.8 | 17.6 | 41.2 | 32.4 | 14.7 b | 85.3 b | 0 b | 50.0 | 50.0 |
| 30 days | |||||||||
| Control | 29.4 a | 38.2 a | 32.4 a | 0 a | 67.6 a | 32.4 a | 0 a | 88.2 a | 11.8 a |
| MTA | 34.8 a | 52.2 a | 13.0 a | 0 a | 80.4 a | 19.6 a | 0 a | 60.9 b | 39.1 b |
| iRoot SP | 14.7 à | 38.2 à | 47.1 à | 0 à | 91.1 a | 8.8 a | 0 a | 55.9 b | 44.1 b |
| BC Sealer HiFlow | 8.8 à | 44.1 à | 47.1 à | 0 à | 58.8 ã | 41.2 ã | 0 ã | 61.8 b | 38.2 b |
| 150 days | |||||||||
| Control | 68.9 a | 23.0 a | 8.2 a | 0 a | 68.9 a | 31.1 a | 0 a | 95.1 | 4.9 |
| MTA | 41.9 a | 48.8 a | 9.3 a | 0 a | 87.5 b | 12.5 b | 0 b | 95.8 | 4.2 |
| iRoot SP | 58.5 a | 37.7 a | 3.8 a | 0 a | 96.2 b | 3.8 b | 0 b | 83.0 | 17.0 |
| BC Sealer HiFlow | 73.7 à | 26.3 à | 0 à | 0 à | 97.4 b | 2.6 b | 0 b | 92.1 | 7.9 |
Different letters “a” and “b” in the same column indicate that there is a statistically significant difference between the endodontic material treatment groups versus the control group in terms of the inflammatory score, the macrophage score or the necrosis score at each time point (p < 0.05). “à” at 30 days indicates that there is no significant difference among MTA, SP and HiFlow versus the control, but there are significant differences between MTA and SP or HiFlow in terms of the inflammatory score. “ã” at 30 days indicates that there is no significant difference among MTA, SP and HiFlow versus the control, but there is a significant difference between HiFlow and SP in terms of the macrophage score. “à” at 150 days indicates that there is no significant difference among MTA, SP and HiFlow versus the control, but there is a significant difference between HiFlow and MTA. * Inflammatory score: 0, no reaction (no or fewer than 10 inflammatory cells); 1, mild (between 10 and 25 cells); 2, moderate (between 26 and 65 cells); 3, severe (more than 65 cells). † Macrophage score: 0, no reaction (no or fewer than 10 macrophages); 1, mild (between 10 and 30 cells); 2, moderate or severe (more than 30 cells). # Necrosis area: 0, absent; 1, present.